- Home
- AUPH vs CHY Comparison
AUPH vs CHY Comparison
Compare AUPH & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUPH | CHY |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.0B |
| IPO Year | 2014 | 2003 |
Fundamental Metrics
Financial Performance| Metric | AUPH | CHY |
|---|---|---|
| Price | $16.53 | $11.92 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 741.3K | 138.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | $31.31 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $10.34 | $10.41 |
| 52 Week High | $19.25 | $13.91 |
Technical Indicators
Market Signals| Indicator | AUPH | CHY |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 32.27 |
| Support Level | $15.65 | $11.35 |
| Resistance Level | $17.02 | $12.12 |
| Average True Range (ATR) | 0.43 | 0.25 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 51.53 | 19.44 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.